Stocks TelegraphStocks Telegraph
Stock Ideas

KDNY Financial Statements and Analysis

NASDAQ : KDNY

Chinook Therapeutics, Inc.

$40.39
0.09+0.22%
At Close 4:00 PM
Not Actively Trading
60.07
BESG ScoreESG Rating

KDNY FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

KDNY Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

Date2023-06-302023-03-312022-12-312022-09-302022-06-30
reported currencyUSDUSDUSDUSDUSD
calendar year20232023202220222022
periodQ2Q1Q4Q3Q2
revenue1.008M1.828M512.00K2.501M418.00K
cost of revenue433.00K433.00K429.00K431.00K429.00K
gross profit575.00K1.395M83.00K2.07M-11.00K
gross profit ratio0.570.7630.1620.828-0.026
research and development expenses57.897M50.883M42.952M41.984M30.023M
general and administrative expenses12.992M11.404M9.765M10.023M8.635M
selling and marketing expenses00000
selling general and administrative expenses12.992M11.404M9.765M10.023M8.635M
other expenses2.243M433.00K433.00K431.00K429.00K
operating expenses71.391M62.72M53.15M52.438M39.087M
cost and expenses71.391M62.72M53.15M52.438M39.087M
interest income00000
interest expense0-5.152M4.821M-1.69M-767.00K
depreciation and amortization1.912M-1.617M12.522M16.751M-2.703M
ebitda-69.898M-63.035M-47.384M-40.927M-39.388M
ebitda ratio-69.343-34.483-92.547-16.364-94.23
operating income-72.626M-61.418M-59.906M-57.678M-36.685M
operating income ratio-72.05-33.598-117.004-23.062-87.763
total other income expenses net1.427M3.102M2.447M1.69M767.00K
income before tax-68.956M-58.316M-57.459M-55.988M-35.918M
income before tax ratio-68.409-31.902-112.225-22.386-85.928
income tax expense-2.012M1.861M4.341M-1.699M1.73M
net income-66.944M-60.177M-61.80M-54.289M-37.648M
net income ratio-66.413-32.92-120.703-21.707-90.067
eps-0.94-0.85-0.89-0.80-0.61
eps diluted-0.94-0.85-0.89-0.80-0.61
weighted average shs out71.592M70.703M69.217M67.779M61.983M
weighted average shs out dil71.592M70.703M69.217M67.779M61.983M
Graph

KDNY Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

Date2023-06-302023-03-312022-12-312022-09-302022-06-30
reported currencyUSDUSDUSDUSDUSD
calendar year20232023202220222022
periodQ2Q1Q4Q3Q2
cash and cash equivalents127.149M118.495M115.438M126.072M145.927M
short term investments170.016M231.881M262.887M247.211M216.687M
cash and short term investments297.165M350.376M378.325M373.283M362.614M
net receivables3.102M2.444M1.091M2.919M3.115M
inventory00000
other current assets5.15M5.824M6.176M5.468M5.67M
total current assets305.417M358.644M385.592M381.67M371.399M
property plant equipment net59.109M64.319M65.878M67.373M69.777M
goodwill117.00K117.00K117.00K117.00K117.00K
intangible assets59.971M60.404M60.837M61.27M61.701M
goodwill and intangible assets60.088M60.521M60.954M61.387M61.818M
long term investments47.956M50.855M52.26M70.73M89.132M
tax assets00000
other non current assets16.241M9.536M9.40M9.176M9.116M
total non current assets183.394M185.231M188.492M208.666M229.843M
other assets00000
total assets488.811M543.875M574.084M590.336M601.242M
account payables16.362M9.774M9.751M11.843M4.907M
short term debt4.268M5.085M4.948M4.81M4.701M
tax payables45.00K345.00K00331.00K
deferred revenue29.286M0000
other current liabilities2.556M36.105M36.136M28.083M19.873M
total current liabilities52.472M50.964M50.835M44.736M29.481M
long term debt29.717M33.178M34.494M35.759M37.166M
deferred revenue non current00000
deferred tax liabilities non current5.076M5.076M5.076M735.00K735.00K
other non current liabilities44.507M42.264M41.738M34.47M26.729M
total non current liabilities79.30M80.518M81.308M70.964M64.63M
other liabilities00000
capital lease obligations33.985M38.263M39.442M40.569M41.867M
total liabilities131.772M131.482M132.143M115.70M94.111M
preferred stock00000
common stock7.00K7.00K7.00K6.00K6.00K
retained earnings-546.752M-479.808M-419.631M-357.077M-301.098M
accumulated other comprehensive income loss-1.325M-1.711M-3.164M-3.623M-2.531M
other total stockholders equity905.109M893.905M864.729M835.33M810.754M
total stockholders equity357.039M412.393M441.941M474.636M507.131M
total equity357.039M412.393M441.941M474.636M507.131M
total liabilities and stockholders equity488.811M543.875M574.084M590.336M601.242M
minority interest00000
total investments211.216M273.081M315.147M317.941M305.819M
total debt33.985M38.263M39.442M40.569M41.867M
net debt-93.164M-80.232M-75.996M-85.503M-104.06M
Graph

KDNY Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

Date2023-06-302023-03-312022-12-312022-09-302022-06-30
reported currencyUSDUSDUSDUSDUSD
calendar year20232023202220222022
periodQ2Q1Q4Q3Q2
deferred income tax-3.332M04.341M00
stock based compensation9.192M7.91M5.706M5.319M4.76M
change in working capital-5.449M-2.335M5.487M14.867M-605.00K
accounts receivables-658.00K-1.353M1.828M196.00K-168.00K
inventory00000
accounts payables6.51M13.00K-2.316M7.419M-4.468M
other working capital-11.301M-995.00K5.975M7.252M4.031M
other non cash items3.426M2.629M8.922M9.211M1.61M
net cash provided by operating activities-61.195M-50.668M-36.828M-25.313M-30.618M
investments in property plant and equipment-619.00K-927.00K-683.00K-369.00K-227.00K
acquisitions net0-97.50M-200.842M00
purchases of investments-27.474M-64.14M-64.991M-81.978M-73.18M
sales maturities of investments96.10M97.50M68.147M69.216M39.645M
other investing activites097.50M200.842M00
net cash used for investing activites68.007M32.433M2.473M-13.131M-33.762M
debt repayment00000
common stock issued019.60M14.081M18.381M113.505M
common stock repurchased00000
dividends paid00000
other financing activites01.666M9.613M453.00K-6.364M
net cash used provided by financing activities2.012M21.266M23.694M18.834M107.141M
effect of forex changes on cash-170.00K26.00K27.00K-245.00K-334.00K
net change in cash8.654M3.057M-10.634M-19.855M42.427M
cash at end of period129.223M120.569M117.512M128.146M148.001M
cash at beginning of period120.569M117.512M128.146M148.001M105.574M
operating cashflow-61.195M-50.668M-36.828M-25.313M-30.618M
capital expenditure-619.00K-927.00K-683.00K-369.00K-227.00K
free cash flow-61.814M-51.595M-37.511M-25.682M-30.845M
Graph

Frequently Asked Questions

How did Chinook Therapeutics, Inc. do last quarter? What was its Total Revenue and Cost of Revenue?

A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, KDNY generated $1.01M in revenue last quarter, while its costs came in at $433.00K.

Last quarter, how much Gross Profit did Chinook Therapeutics, Inc. report?

A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. Chinook Therapeutics, Inc. reported a $575.00K Gross Profit for the quarter ended Jun 30, 2023.

Have KDNY's Total Operating Expenses and Operating Income been favorable recently?

Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. KDNY incurred $71.39M worth of Operating Expenses, while it generated -$72.63M worth of Operating Income.

How much Net Income has KDNY posted recently?

The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from Chinook Therapeutics, Inc., the company generated -$66.94M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.

At the end of the last quarter, how much Cash and Equivalents did Chinook Therapeutics, Inc. have?

The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to Chinook Therapeutics, Inc. as of the end of the last quarter was $127.15M.

What are KDNY's Total Net Receivables for the last quarter?

Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, KDNY had Total Net Receivables of $3.10M.

In terms of Total Assets and Current Assets, where did Chinook Therapeutics, Inc. stand at?

An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of KDNY were $305.42M, while the Total Assets stand at $488.81M.

As of the last quarter, how much Total Debt did Chinook Therapeutics, Inc. have?

The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of KDNY's debt was $33.99M at the end of the last quarter.

What were KDNY's Total Liabilities during the last reported quarter?

A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, KDNY reported total liabilities of $131.77M.

How much did KDNY's Working Capital change over the last quarter?

Working Capital Change for KDNY was -$5.45M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.

KDNY generated how much cash from operating activities?

An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. KDNY generated -$61.20M of Cash from Operating Activities during its recently reported quarter.

What was KDNY's latest reported Net Change in Cash?

An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. KDNY reported a $8.65M Net Change in Cash in the most recent quarter.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph